Gapping up
In reaction to strong earnings/guidance: GIMO +20.3%, MTW +14.1%,QLGC +11.1%, FLEX +9.2%, FTNT +9.1%, SWKS +6.5%, SHOR +5.7%, ALGN+5%, USAT +4.7%, MSFT +4.2%, PFPT +3.8%, STX +3.7%, COHR +2.9%,WRK +2.7%, HON +2.3%, AAL +2%, ARAY +1.7%, V +1.5%, CLGX +1.2%,CLGX +1.2%, WDC +0.9%, PTR +0.8%, FICO +0.7%, WHR +0.7%, AMGN+0.5%
M&A news: BLT +0.9% (updates on go-shop period, none of the 91 parties contacted submitted an alternative acquisition proposal)
Other news: INO +9% (cont strength), STRP +4.6% (Blackrock filed a passive 5.3% stake), RDY +4.4% (receives FDA approval for ZEMBRACE SymTouch injection), OSTK +2% (accepted $20 mln to settle market manipulation case), MRK +2% (receives FDA approval of ZEPATIER), FIT+2% (modestly rebounding after recent weakness), CSIQ +1.9% (to receive a financing package of up to $70 mln in loans and equity investment from IFC), AZN +1.8% (Allergan to collaborate with AstraZeneca (AZN) to develop and commercialize ATM-AVI), SUNE +1.6% (presenting at investor conf today), FCH +1.2% ( responds to Land and Buildings and provides update on its strategic plan), PII +1% ( increases quarterly dividend 4% to $0.55/share; approves increase in stock repurchase authorization by 7.5 mln shares), GGP +0.8% (following late surge higher on renewed BAM takeover speculation)
Analyst comments: ICPT +2.7% (upgraded to Equal-Weight from Underweight at Morgan Stanley), KITE +2.5% (initiated with a Buy at Sun Trust Rbsn Humphrey), JCP +2.5% (upgraded to Neutral from Underperform at Credit Suisse), SCSS +2.3% (upgraded to Outperform at Wedbush), JNPR +1.9% (upgraded to Outperform from Mkt Perform at Bernstein), JUNO +1.3% (initiated with a Buy at Sun Trust Rbsn Humphrey), JBLU +1.3% (upgraded to Buy from Hold at Evercore ISI)
In reaction to strong earnings/guidance: GIMO +20.3%, MTW +14.1%,QLGC +11.1%, FLEX +9.2%, FTNT +9.1%, SWKS +6.5%, SHOR +5.7%, ALGN+5%, USAT +4.7%, MSFT +4.2%, PFPT +3.8%, STX +3.7%, COHR +2.9%,WRK +2.7%, HON +2.3%, AAL +2%, ARAY +1.7%, V +1.5%, CLGX +1.2%,CLGX +1.2%, WDC +0.9%, PTR +0.8%, FICO +0.7%, WHR +0.7%, AMGN+0.5%
M&A news: BLT +0.9% (updates on go-shop period, none of the 91 parties contacted submitted an alternative acquisition proposal)
Other news: INO +9% (cont strength), STRP +4.6% (Blackrock filed a passive 5.3% stake), RDY +4.4% (receives FDA approval for ZEMBRACE SymTouch injection), OSTK +2% (accepted $20 mln to settle market manipulation case), MRK +2% (receives FDA approval of ZEPATIER), FIT+2% (modestly rebounding after recent weakness), CSIQ +1.9% (to receive a financing package of up to $70 mln in loans and equity investment from IFC), AZN +1.8% (Allergan to collaborate with AstraZeneca (AZN) to develop and commercialize ATM-AVI), SUNE +1.6% (presenting at investor conf today), FCH +1.2% ( responds to Land and Buildings and provides update on its strategic plan), PII +1% ( increases quarterly dividend 4% to $0.55/share; approves increase in stock repurchase authorization by 7.5 mln shares), GGP +0.8% (following late surge higher on renewed BAM takeover speculation)
Analyst comments: ICPT +2.7% (upgraded to Equal-Weight from Underweight at Morgan Stanley), KITE +2.5% (initiated with a Buy at Sun Trust Rbsn Humphrey), JCP +2.5% (upgraded to Neutral from Underperform at Credit Suisse), SCSS +2.3% (upgraded to Outperform at Wedbush), JNPR +1.9% (upgraded to Outperform from Mkt Perform at Bernstein), JUNO +1.3% (initiated with a Buy at Sun Trust Rbsn Humphrey), JBLU +1.3% (upgraded to Buy from Hold at Evercore ISI)